erratum report replac origin version publish novemb
gross margin updat state correct version
gross margin updat impact ep estim
edit affect conclus author et
away cgm awar adopt climb arent
chase might neutral
weve said say dexcom
deliv incred quarter best consensu revenu nearli
achiev highest growth rate three year record absolut dollar
growth y/i basi revenu guidanc full year rais
midpointa increas account beat
point manag confid busi commerci channel
signific driver growth patient revenu quarter
intern sale post strong y/i sequenti growth well underli
continu grow awar cgm technolog dxcm reput
offer premium product capac stretch limit management
commit increas manufactur significantli near term
win payor contract meaning partnership improv patient access
expect adopt continu expand rapidli said worri
price get exclus doubt matter
longer term might increas revenu outlook remain
neutral base valuat view point price pressur
probabl matter like wish upgrad multipl
beat front price may matter futur
problem robust demand well temporari product
line outag late littl impact quarter earli mean
co still play catch capac short-term drop product
includ latest revenu guidanc could upsid rang
capac made quarter remain track
doubl capac end doubl
besid top line post impress oper leverag sg
spend notabl lower expect oper margin guidanc
rais full year think leverag continu
revenu come profit pharmaci channel
remain track limit launch still slate late broader
launch follow manag emphas desir avoid
capac issu accompani work get ahead
may earli say compon collabor
rate may impact control-iq roll-out
model bolu adopt relat launch uncertain
near-term dynam think could underappreci driver
valuat rate neutral risk discuss
idc btig estim compani document
million except per share amount
believ time cgm primari method monitor glucos insulin-depend
commentari competit emphas posit impact term referr volum potenti new
patient feel new competit also put pressur price next year take user
concern competit price like immedi and/or increas spend expect meet
revenu estim wonder happen price beyond
competit announc launch
continu robust adopt
acceler adopt
faster shift toward pharmaci channel greater volum uplift far outweigh
continu stabil possibl favor price environ
slowdown adopt
visibl impact cgm competit
drop price due competit reimburs
dedic improv live
diabet cgm asid
creat wide
recogn cgm product
system compani
entrench diabet
manag ecosystem stand
benefit innov
develop intern extern
high qualiti open
partnership research
hacker pump compani
outpac consensu expect top sale estim gross margin
bp lower project off-set well-control oper expens particularli sg
spend combin larg revenu beat high ebit margin compani report non-gaap ep
cent better forecast
updat model strong sale beat updat guidanc new forecast includ meaning
increas sensor revenu slightli lower hardwar revenu land total revenu top end
revis guidanc outyear increas new patient add push hardwar revenu bit also add
significantli sensor revenu forecast
 reduc gross margin reflect guidanc commentari around manufactur capac
maintain gross margin outlook outyear oper spend especi sg expens low
quarter trim sg spend percentag revenu maintain opex percentag
revenu sinc match guidanc
includ sizabl beat model non-gaap ep prior prior
actualsbtig estimate variancetot revenu net incom spend spend opex spend btig estim compani filingsvari
rate neutral believ current multipl estim ntm ev/sal expens given
potenti price pressur face increas competit valuat seem support mani
investor risk rate includ competit increas spend chang revenu growth rate fda product
recal reimburs price pressur
exhibit comp tabl large-cap peer
bpsebit bp btig estim compani filingsnewold changentm inc ingnnot sciencesexasbuy medicalwmginot factset data btig estimatespr ptpricemarket cap bev/salescagrev/gross profit
incom product develop grant oper expens tax expens net incom share net incom net incom analysisgross profit net incom revenu oper oper btig estim compani report
revenu eworldwid patient basebegin new drop patient re-ord disclos histor patient price revenu re-ord disclos histor patient price revenu hardwar revenu sensor kit order per quarter disclos histor per sensor revenu product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
